X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8850) 8850
Book Review (1678) 1678
Publication (764) 764
Book Chapter (52) 52
Conference Proceeding (13) 13
Dissertation (9) 9
Magazine Article (7) 7
Book / eBook (2) 2
Paper (2) 2
Data Set (1) 1
Reference (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7862) 7862
male (4928) 4928
humans (4844) 4844
animals (4147) 4147
phosphodiesterase inhibitors - pharmacology (1924) 1924
rats (1915) 1915
female (1846) 1846
pharmacology & pharmacy (1843) 1843
sildenafil citrate (1741) 1741
sildenafil (1597) 1597
middle aged (1541) 1541
phosphodiesterase inhibitors - therapeutic use (1540) 1540
erectile dysfunction (1396) 1396
adult (1272) 1272
erectile dysfunction - drug therapy (1194) 1194
phosphodiesterase (1170) 1170
mice (1142) 1142
urology & nephrology (1113) 1113
aged (1037) 1037
treatment outcome (1017) 1017
dose-response relationship, drug (985) 985
phosphodiesterase inhibitors - administration & dosage (918) 918
tadalafil (860) 860
neurosciences (795) 795
impotence (791) 791
abridged index medicus (778) 778
piperazines - therapeutic use (768) 768
analysis (756) 756
rats, sprague-dawley (721) 721
nitric oxide (712) 712
phosphodiesterase inhibitors (690) 690
purines (687) 687
disease models, animal (683) 683
phosphodiesterase 5 inhibitors - therapeutic use (675) 675
sulfones (666) 666
drug therapy (641) 641
nitric-oxide (621) 621
piperazines - pharmacology (619) 619
care and treatment (595) 595
cardiac & cardiovascular systems (587) 587
cyclic amp - metabolism (579) 579
double-blind (579) 579
research (575) 575
administration, oral (572) 572
piperazines - administration & dosage (559) 559
time factors (549) 549
rats, wistar (545) 545
expression (533) 533
double-blind method (524) 524
health aspects (498) 498
phosphodiesterase inhibitors - adverse effects (494) 494
men (491) 491
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (488) 488
inflammation (473) 473
rodents (473) 473
cyclic gmp - metabolism (468) 468
hypertension, pulmonary - drug therapy (468) 468
biochemistry & molecular biology (459) 459
pulmonary hypertension (456) 456
respiratory system (455) 455
efficacy (453) 453
phosphodiesterase 5 inhibitors - administration & dosage (449) 449
phosphodiesterase inhibitor (443) 443
physiology (441) 441
therapy (435) 435
medicine & public health (431) 431
hypertension (427) 427
rolipram (426) 426
camp (425) 425
drug therapy, combination (420) 420
in vitro techniques (417) 417
sulfones - therapeutic use (416) 416
inhibitors (408) 408
physiological aspects (396) 396
risk factors (393) 393
dosage and administration (383) 383
phosphodiesterase 5 inhibitors - pharmacology (382) 382
safety (379) 379
nitric-oxide synthase (375) 375
inhibition (372) 372
in-vitro (365) 365
piperazines - adverse effects (361) 361
vardenafil (361) 361
sulfones - administration & dosage (359) 359
phosphoric diester hydrolases - metabolism (358) 358
sulfones - pharmacology (357) 357
cell biology (356) 356
phosphodiesterases (353) 353
article (346) 346
cells (343) 343
cgmp (343) 343
mice, inbred c57bl (343) 343
vasodilator agents - therapeutic use (342) 342
blood pressure - drug effects (341) 341
vardenafil dihydrochloride (340) 340
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (337) 337
apoptosis (336) 336
erectile dysfunction - etiology (331) 331
activation (328) 328
cells, cultured (328) 328
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8677) 8677
Russian (46) 46
German (44) 44
French (38) 38
Japanese (35) 35
Chinese (21) 21
Spanish (15) 15
Portuguese (7) 7
Italian (4) 4
Korean (3) 3
Hungarian (2) 2
Polish (2) 2
Turkish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Journal Article
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 08/2017, Volume 60, Issue 15, pp. 6622 - 6637
Journal Article
Neurology, ISSN 0028-3878, 06/2014, Volume 82, Issue 23, pp. 2085 - 2091
OBJECTIVE:To determine whether phosphodiesterase type 5 (PDE5) inhibition can alleviate exercise-induced skeletal muscle ischemia in boys with Duchenne... 
NNOS | SKELETAL-MUSCLE | PERINDOPRIL | SILDENAFIL | SARCOLEMMA | HUMANS | ANGIOTENSIN-II | DYSFUNCTION | EXERCISE | CLINICAL NEUROLOGY | MDX MOUSE MODEL | Piperazines - administration & dosage | Forearm - diagnostic imaging | Phosphodiesterase 5 Inhibitors - adverse effects | Sympathetic Nervous System - drug effects | Humans | Sulfones - adverse effects | Male | Purines - administration & dosage | Sympathetic Nervous System - physiopathology | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Sulfones - pharmacology | Sildenafil Citrate | Vasoconstriction - physiology | Spectroscopy, Near-Infrared | Muscular Dystrophy, Duchenne - physiopathology | Muscle, Skeletal - drug effects | Forearm - blood supply | Ultrasonography | Purines - adverse effects | Piperazines - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacology | Child | Carbolines - adverse effects | Muscle, Skeletal - blood supply | Muscular Dystrophy, Duchenne - drug therapy | Purines - pharmacology | Purines - pharmacokinetics | Phosphodiesterase 5 Inhibitors - administration & dosage | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Muscular Dystrophy, Duchenne - complications | Piperazines - adverse effects | Piperazines - pharmacology | Vasoconstriction - drug effects | Tadalafil | Ischemia - drug therapy | Muscle, Skeletal - physiopathology | Adolescent | Exercise - physiology | Carbolines - pharmacokinetics | Carbolines - pharmacology | Ischemia - etiology | Sulfones - administration & dosage | Index Medicus | Abridged Index Medicus | 185
Journal Article
Journal Article
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 11/2012, Volume 157, Issue 10, pp. 681 - 691
Journal Article
Circulation, ISSN 0009-7322, 05/2012, Volume 125, Issue 19, pp. 2323 - 2333
Background-cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy. However, it has never been ascertained whether phosphodiesterase... 
fibrosis | phosphodiesterase inhibitors heart failure | diabetes mellitus type 2 | cardiac magnetic resonance imaging | diabetic diastolic heart failure | CARDIAC & CARDIOVASCULAR SYSTEMS | PULMONARY-HYPERTENSION | ENDOTHELIAL DYSFUNCTION | SILDENAFIL CITRATE | AORTIC-STENOSIS | DIASTOLIC HEART-FAILURE | HYPERTROPHY | FLOW-MEDIATED DILATATION | NITRIC-OXIDE | VALVE-REPLACEMENT | PERIPHERAL VASCULAR DISEASE | TYPE-5 INHIBITION | Piperazines - administration & dosage | Diabetic Cardiomyopathies - drug therapy | Follow-Up Studies | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Magnetic Resonance Imaging - methods | Male | Purines - administration & dosage | Torsion, Mechanical | Sildenafil Citrate | Hypertrophy, Left Ventricular - pathology | Purines - adverse effects | Cardiac Imaging Techniques - methods | Hypertrophy, Left Ventricular - drug therapy | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Diabetes Mellitus, Type 2 - complications | Phosphodiesterase 5 Inhibitors - administration & dosage | Treatment Outcome | Piperazines - adverse effects | Diabetic Cardiomyopathies - pathology | Aged | Ventricular Remodeling - drug effects | Sulfones - administration & dosage | Care and treatment | Magnetic resonance imaging | Cardiomyopathy | Clinical trials | Diagnosis | Phosphodiesterases | Heart diseases | Health aspects | Methods | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 05/2013, Volume 169, Issue 2, pp. 449 - 461
Background and Purpose We have evaluated the influence of calcium-activated potassium channels (KCa) activation on cGMP-mediated relaxation in human penile... 
NS1619 | PDE5 | human corpus cavernosum | human penile resistance arteries | calcium‐activated potassium channels | diabetes | sildenafil | erectile dysfunction | LARGE-CONDUCTANCE | POTASSIUM CHANNELS | SMOOTH-MUSCLE TONE | SILDENAFIL CITRATE | BKCA CHANNEL | calcium-activated potassium channels | NEUROGENIC CONTRACTIONS | NS-8 | ENDOTHELIAL-CELLS | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | INTERMEDIATE-CONDUCTANCE | Piperazines - administration & dosage | Erectile Dysfunction - physiopathology | Humans | Middle Aged | Male | Purines - administration & dosage | Sulfones - pharmacology | Dose-Response Relationship, Drug | Sildenafil Citrate | Penis - drug effects | Erectile Dysfunction - drug therapy | Potassium Channels, Calcium-Activated - metabolism | Adult | Diabetes Mellitus, Experimental - complications | Phosphodiesterase 5 Inhibitors - pharmacology | Penis - blood supply | Vasodilator Agents - pharmacology | Purines - pharmacology | Phosphodiesterase 5 Inhibitors - administration & dosage | Rats | Erectile Dysfunction - etiology | Piperazines - pharmacology | Rats, Sprague-Dawley | Tadalafil | Animals | Cyclic GMP - metabolism | Electric Stimulation Therapy - methods | Penis - metabolism | Benzimidazoles - pharmacology | Aged | Vasodilation - drug effects | Nitric Oxide - metabolism | Vasodilator Agents - administration & dosage | Carbolines - pharmacology | Sulfones - administration & dosage | Diabetics | Diabetes | Impotence | Vasodilators | Arteries | Index Medicus | Research Papers
Journal Article